Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study (NCT05802186)
A Single-Arm Phase II Study of Personalized Dose Guidance for Stereotactic Body Radiotherapy (SBRT) in Patients With Lung Tumors
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors that has spread from another primary site to the lung (metastatic). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Even with the high precision of SBRT, disease persistence or reappearance (local recurrence) can still occur, which could be attributed to the radiation dose. AI has been used in other areas of healthcare to automate and improve various aspects of medical science. Because the relationship of dose and local recurrence indicates that dose prescriptions matter, decision support systems to help guide dose based on personalized prediction AI algorithms could better assist providers in prescribing the radiation dose of lung stereotactic body radiation therapy treatment.
Who can join: Review the eligibility criteria below.
Location: Northwestern University — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
- Computed Tomography (PROCEDURE)
- Magnetic Resonance Imaging (PROCEDURE)
- Positron Emission Tomography (PROCEDURE)
- Quality-of-Life Assessment (OTHER)
- Radiology, Treatment Planning (OTHER)
- Stereotactic Body Radiation Therapy (RADIATION)
- X-Ray Imaging (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Northwestern University — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (312) 695-1301
Email: cancer@northwestern.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Carcinoma
- MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer — Rochester, Minnesota
- Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer — Houston, Texas
- Screening for Lung Cancer in Older Patients (PLCO Screening Trial) — Bethesda, Maryland
- Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial — Columbus, Ohio
- Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer — Aurora, Colorado
- Testing the SurVaxM Vaccine for Lung Cancer Prevention — Aurora, Colorado
Explore by condition: All Lung Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.